All In Biotech

Drug Trial Radar · NCT07161999

Study of COYA 302 for the Treatment of ALS

Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension and Open Label Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Apr 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Coya TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) in a 1:1:1 ratio for 24 weeks in the double-blind (DB) period. Those who complete this part of the study will be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). Upon completion of the EXT phase of the study, participants will be invited to participate in an open label extension (OLE). The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • COYA 302Drug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R)Time frame: Baseline to Week 24

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

  • Nova Southeastern University

    Davie, Florida

  • University of Florida Clinical and Translational Research Center

    Gainesville, Florida

  • University Of Miami

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern

    Chicago, Illinois

  • Johns Hopkins

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Washington University

    St Louis, Missouri

  • Neurology Associates, P.C. Somnos Clinical Research

    Lincoln, Nebraska

  • Columbia University Medical Center ALS Center

    New York, New York

  • Thomas Jefferson University-Weinberg ALS Center

    Philadelphia, Pennsylvania

  • Temple Neurology

    Philadelphia, Pennsylvania

  • Austin Neuromuscular Center; National Neuromuscular Research Institute, PLLC

    Austin, Texas

  • Texas Neurology, PA

    Dallas, Texas

  • Houston Methodist Stanley H. Appel Department of Neurology

    Houston, Texas

  • The University of Texas Health Science Center

    San Antonio, Texas

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • London Health Sciences Center

    London, Ontario, Canada

  • University of Toronto/Sunnybrook Health Sciences Center

    Toronto, Ontario, Canada

  • Hopital Neurologique de Montreal

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.